

Date: October 29, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Investor Presentation for Q2 & H1FY27

Dear Sir/Ma'am,

In terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our intimation dated October 22, 2026 and October 23, 2026 regarding the Earnings Conference Call, we enclose herewith the Investor Presentation for Q2 & H1FY27.

The aforesaid information will be hosted on the Company's website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

**SHILPA
SHARMA**

Digitally signed by SHILPA
SHARMA
DN: cn=SHILPA SHARMA, c=IN,
o=Personal,
email=csshilpa.agarwal@gmail.com
Date: 2026.10.29 14:41:56 +05'30'

Shilpa Sharma

Company Secretary & Compliance Officer
Membership Number: A34516

Enclosure: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Investor Presentation

October 2026



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Senores Pharmaceuticals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



Financial & Operational Highlights Q2 & H1FY27

Key Highlights – Q2 & H1FY27

Consistently strong delivery

REVENUE GROWTH

25%

Q2 FY27

30%

H1 FY27

EBITDA GROWTH

38.4%

Q2 FY27

58.2%

H1 FY27

EBITDA MARGIN EXPANSION

~290 bps

Q2 FY27

~530 bps

H1 FY27

CASH FROM OPERATIONS

₹38 Cr

H1 FY27

₹31 Cr

H1 FY26



Strong EBITDA growth even while investing for the future

Q2 and H1 FY27 EBITDA grew 38.3% and 58.2% despite investments in Apnar (last 6 months) and ongoing investments in Zoraya & Amerisyn (revenues to ramp up over the next 12 months). Excluding these investments, which will reap future benefits, EBITDA growth would have been much higher.

What drives the H2 outlook



Robust approved & pipeline products

Strong growth visibility – H2 expected to be considerably better than H1 owing to anticipated launches



R&D intensity at 11% of revenue

R&D expenses stood at 11% of revenue in H1 FY27



Forward integration

Zoraya and Amerisyn to begin contributing to revenues from H2 FY27

Senores group companies

INDIA



**APNAR PHARMA
PVT. LTD.**
(A subsidiary of
Senores Pharmaceuticals Ltd.)

USA



**AAVIS
PHARMACEUTICALS**
REINVENTING HEALTHCARE
Havix Group Inc.
D/B/A Aavis Pharmaceuticals
(A subsidiary of
Senores Pharmaceuticals Ltd.)




AMERISYN
Amerisyn LLC (A subsidiary of Senores
Pharmaceuticals Inc.)

Regulated Market Owned Product Portfolio & Visibility

	Owned ANDAs			Corresponding ANDA Products*		Key Highlights
	Q2FY26	Q2FY27		Q2FY26	Q2FY27	
Approved ANDAs	34	64		81	207	- Commercialized 3 new strengths in Q2FY27 under existing ANDAs, including 2 being sold in the US for the first time by any company. - Received approval for 1 ANDA and 3 sANDA's in Q2FY27. 41 ANDAs with Corresponding 153 ANDA Products* to be launched - Expecting 13 ANDAs with 41 strengths to be commercialized in government channel in H2FY27. - Robust Pipeline of 41 molecules with 130 unique strengths under development.
Commercialized ANDAs	16	23		32	54	
ANDAs Yet To Launch	18	41		49	153	
Molecules Under Development	35	41		70	130	


*ANDA Products represents individual strengths associated with an ANDA

CDMO / CMO & Emerging Market Opportunity




Consolidated Financial Highlights – Q2 & H1FY27


Revenue (₹ Crs)




EBITDA (₹ Crs)




PAT (₹ Crs)




Gross Margin (%)



EBITDA Margin (%)



PAT Margin (%)



Segmental Financial Highlights – Q2 & H1FY27

Segment Revenue (₹ Crs)	Q2FY27	Q2FY26	Y-o-Y	H1FY27	H1FY26	Y-o-Y
Regulated Markets	136.7	106.9	27.9%	264.5	196.9	34.3%
Emerging Markets	38.4	31.7	21.2%	76.0	60.7	25.3%
Branded Generics	9.5	11.9	-20.5%	17.5	20.2	-13.4%
Others	7.8	3.4	126.2%	14.6	8.7	67.2%
Total Revenue	192.3	153.9	24.9%	372.5	286.5	30.0%

- **Regulated Markets** - EBIDTA Margin for H1 FY27 stood at ~42%. Regulated Markets contributed to **71% of total revenue** in H1FY27
- **Emerging Markets** - EBIDTA Margin for H1 FY27 stood at ~9%. Emerging Markets contributed **20% of total revenue** in H1FY27

Consolidated Profit & Loss Account – Q2 & H1FY27

Consolidated P&L (₹ Crs)	Q2FY27	Q2FY26	Y-o-Y	H1FY27	H1FY26	Y-o-Y
Revenue from Operations	192.3	153.9	24.9%	372.5	286.5	30.0%
Cost of Goods Sold	66.6	57.1		132.3	118.4	
Gross Profit	125.8	96.9	29.8%	240.2	168.1	42.9%
Gross Margin (%)	65.4%	62.9%	250 bps	64.5%	58.7%	580 bps
Employee Cost	32.4	29.6		62.3	51.3	
Other Expenses	35.7	25.6		66.5	46.4	
EBITDA	57.7	41.7	38.3%	111.4	70.4	58.2%
EBITDA Margin (%)	30.0%	27.1%	290 bps	29.9%	24.6%	530 bps
Other Income	8.9	13.2		11.8	22.0	
Depreciation	10.3	8.1		20.2	14.1	
Finance Cost	8.8	6.2		15.9	11.2	
PBT	47.6	40.6	17.1%	87.0	67.1	29.7%
Tax Charge / (Credit)	11.0	10.5		20.0	15.8	
Profit after Tax	36.6	30.1	24.7%	67.0	51.3	32.6%
PAT Margin (%)	19.0%	19.5%	-50 bps	18.0%	17.9%	10 bps
Minority Interest	(2.9)	(2.3)		(3.2)	(0.8)	
Profit after Tax and Minority Interest	39.5	32.4	22.0%	70.2	52.1	34.7%
PAT Margin (%) after Minority Interest	20.5%	21.0%	-50 bps	18.9%	18.2%	70 bps

Consolidated Balance Sheet

ASSETS (₹ Crs)	Sep-26	Mar-26
Non-Current Assets		
Property, Plant and Equipment	336.2	331.4
Capital Work-in-Progress	31.1	17.5
Right of Use Assets	23.7	13.9
Goodwill	46.6	46.6
Other Intangible Assets	109.1	106.8
Intangible Assets under Development	311.1	232.0
Investment Property	24.8	24.6
Financial Investments	5.9	4.3
Non-Current Financial Assets	18.9	10.2
Deferred Tax Assets (Net)	2.3	0.0
Other Non-Current Assets	4.7	4.2
Total Non-Current Assets	914.3	791.4
Current Assets		
Inventories	97.6	89.3
Trade Receivables	253.2	324.8
Cash & Cash Equivalents	18.0	45.6
Other Bank Balances	82.7	114.1
Other Current Financial Assets	224.3	172.7
Other Current Assets	90.5	66.0
Total Current Assets	766.3	812.4
Total ASSETS	1,680.6	1,603.8

EQUITY AND LIABILITIES (₹ Crs)	Sep-26	Mar-26
Equity		
Equity Share Capital	46.1	46.1
Other Equity	956.9	887.6
Total Shareholder's Fund	1,002.9	933.6
Non-Controlling Interest	28.6	30.9
Total Equity	1,031.5	964.5
Non-Current Liabilities		
Borrowings	212.9	194.9
Lease Liabilities	19.2	13.2
Provisions	5.4	6.6
Deferred tax liabilities (net)	0.0	0.6
Total Non-Current Liabilities	237.5	215.3
Current Liabilities		
Borrowings	181.6	132.2
Trade Payables	151.1	234.7
Lease Liabilities	3.1	1.8
Other Current Financial Liabilities	12.7	17.6
Other Current Liabilities	22.0	14.8
Provisions	7.2	2.7
Current Tax Liabilities (net)	33.9	20.2
Total Current Liabilities	411.6	424.0
Total EQUITY AND LIABILITIES	1,680.6	1,603.8

Consolidated Abridged Cash Flow Statement

Cash Flow Statement (₹ crs)	H1 FY27	H1 FY26
Profit/(Loss) Before Tax	87.0	67.1
Adjustments for Non-Cash and Non-Operational Expenses / (Incomes)	36.2	7.8
Operating Profit / (Loss) Before Working Capital Changes	123.2	74.9
Changes in Working Capital	(84.7)	(43.5)
Cash from Operations	38.5	31.4
Income Tax (Paid) / Refunded	(9.3)	(7.2)
Net Cash Flow from Operating Activities (A)	29.2	24.2
Net Cash Flow from Investing Activities (B)	(112.2)	41.3
Net Cash Flow from Financing Activities (C)	55.4	(84.9)
Net Change in Cash & Cash Equivalents during the Year (A+B+C)	(27.6)	(19.4)
Cash & Cash Equivalents at the Beginning of the Period	45.6	105.4
Cash & Cash Equivalents at the End of the Period	18.0	86.0

Update on Utilization of Funds from IPO

No.	Object as per Offer Document	Amount as proposed in Offer Document and as Revised (₹ Crs)	Amount utilized till 30 th September 2026 (₹ Crs)	Amount unutilized as on 30th September 2026 (₹ Crs)
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility	41.98	6.98	35.00
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company	73.10	73.10	0.00
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00
4	Funding the working capital requirements of our Company	43.26	43.26	0.00
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes	161.91	161.91	0.00
7	Offer expenses	35.04	34.99	0.05
8	Investment in subsidiary SPI to fund the acquisition of ANDAs	15.39	10.07	5.32
9	Investment in one of the subsidiaries, Apnar, to fund the capital expenditure requirements for expansion of its existing manufacturing facility in Vadodara	25.00	1.69	23.32
10	Investment in one of the subsidiaries, Havix, to fund the capital expenditure requirements for expansion of the existing OSD manufacturing facility in Atlanta	24.63	7.14	17.48
	Total	500.00	418.83	81.17 #

₹ 81.11 crores parked in ICICI Bank FD and ₹ 0.06 crores held in HDFC Bank Account.

Growth Strategies

The background features a dark blue gradient on the left and a lighter blue gradient on the right, separated by a diagonal line. A thick red diagonal stripe runs from the bottom left towards the top right. A white diagonal stripe runs parallel to the red one, slightly above it. Faint, light blue network patterns consisting of interconnected lines and dots are visible in the background.

Growth Strategies



About Senores Pharmaceuticals Limited



Introduction to Senores Pharmaceuticals

Brief Overview

Global Research driven Formulation Focused company engaged in **developing & manufacturing** of pharmaceutical products predominantly for the **Regulated Markets of the US, Canada, UK and others** across various **therapeutic areas**



Niche Product Identification

Company focusses on **identification, development** and **commercialization** of products



R&D Capabilities

Identification, development & manufacturing of diverse range of **specialty, underpenetrated & complex** pharmaceutical products across therapeutic areas and dosage forms




Manufacturing Facilities

- 1 USFDA approved Formulation facility in Atlanta, US
- 2 Formulation facilities in Gujarat, India – out of which 1 is USFDA approved
- 2 API manufacturing facilities in Gujarat, India

Partnerships

Partnerships with leading pharmaceutical companies across Regulated as well as Emerging Markets


At a Glance



Regulated Markets



Emerging Markets



Manufacturing Plant



R&D

Corporate Structure




Senores Pharmaceuticals Inc.
Marketing cum ANDA
Holding Company

US based company holding ANDAs
and mutually exclusive marketing
relationships with customers




Aavis Pharmaceuticals
Manufacturing arm of our
Regulated market offerings

Engaged in the Contract
Development & Manufacturing of
Generic Pharmaceutical
Formulations for the US, Canada




Ratnatris Pharmaceuticals Pvt Ltd.
Caters to Emerging Market

Development, Manufacturing and
Marketing of Generic Pharmaceutical
Formulations



Apnar Pharma Pvt. Ltd.
Caters to Regulated Market

Licensed Manufacturer Serving Regulated
Markets. Operates a manufacturing
facility at Gujarat with 5 ANDAs approved



Entered U.S. Federal Market via
Strategic JV – **Amerisyn LLC**

Senores Pharma's U.S. JV, Amerisyn,
enables direct access to high-barrier
federal and defense markets, driving
future growth.



Zoraya Pharmaceuticals LLC
is a B2C arm for our US Market

Forward integration for the products
which are manufactured at Havix &
Apnar and marketed in US market.



Key Events & Milestones



Incorporated as “**Senores Pharmaceuticals Pvt. Ltd.**” in India.



Incorporated a wholly owned subsidiary, **Senores Pharmaceuticals Inc** in the US




Consolidated presence in emerging markets by acquiring shares in **Ratnatris Pharmaceuticals Pvt. Ltd.**


APNAR PHARMA PVT. LTD.
(A subsidiary of Senores Pharmaceuticals Ltd.)



Acquired a **51% stake in Zoraya Pharmaceuticals, LLC** (Nov 2025)
Acquired **75% stake in Apnar Pharmaceuticals Pvt. Ltd**



Key Strengths of the Company



Four Business Segments



FY26 Revenue
₹ 192 Crs

Regulated Markets Business

Primarily serves the **US, Canada** and **United Kingdom**

USFDA approved **facility in Atlanta, US and Gujarat, India**

Approved - **64** ANDAs with **207** Strengths

Commercialized – **23** ANDAs with **54** Strengths

Pipeline Products – **41** Molecules with **130** Strengths



Emerging & Mid-Tier Markets Business

Develop & manufacture pharmaceutical products for the Emerging & Mid-Tier Markets

WHO-GMP approved **facility at Chhatral, Gujarat**

Present in **40+ Countries**

Approval for manufacturing facility from regulatory bodies of **10 Countries**



Product registration for **558 Products**

Product applications filed for **944 Products**

API Business

Manufacture APIs and caters to the **domestic market** and **SAARC countries**

Naroda facility compliant with Indian GMP

Commercialized **17 APIs**

Branded Generics Business

Supply of critical care injectables across **India** to various **hospitals** through the distributors

Field presence with **104 employees**

Launched **60 Products**

Presence in Regulated Markets through Long-term marketing arrangements

MARKETED PRODUCTS

Business Model

Identify, Develop & Commercialize specialty & complex niche products in mid-market range

- **Long-term Marketing & Distribution Agreements**
- Strength lies in taking a product from **conceptualization to commercialization**
- **64** Approved ANDAs with **207** strengths
- **23** Commercialized ANDAs with **54** strengths



CDMO / CMO

Business Model

Customized formulation, development & manufacturing capabilities for customers


- **Partner with CDMO customers early** in the drug development process
- **Recurring Revenue with Steady & Predictable Cash Flows**
- Contracts for more than **40** products in **US, Canada, UK, South Africa, UAE, Israel, Denmark, Saudi Arabia & Vietnam.**
- Eligible for manufacturing formulations having **controlled substances**
- **Complied for catering to government supplies in the US**



Pharmaceutical companies increasingly favor partnering with one-stop-shop solution providers that seamlessly integrate both development and manufacturing services

Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets

Demonstrated Capability to Propel Products from Conception to Commercialization



Amerisyn – Unlocking the US Government Pharmaceutical Market



The Joint Venture is with a team of Veterans of Army and Air Force.



The team comes with a experience of a decade in Government procurement across Pharmaceuticals, Healthcare and Defence sectors.



The Joint venture has been established to bypass the complex, high barrier market while collaborating with the masters.



Direct supplies to the US Federal government through the Department of Veteran Affairs, Department of Defence, Department of Troop Support etc.



Participating in govt. procurements like VA, FSS & DAPA contracts.



There are nearly 1200 products that the US govt. procures through these various programs including veteran affairs which accounts to \$28 Bn out of \$145 Bn



Zoraya – A step towards Forward Integration



Partnered with a company with 15 years of on-field experience in direct marketing.



The subsidiary has been established to market the products while making a shift from B2B to B2C channel



Acts as a bridge for India-to-U.S. pharma expansion, strengthening Senores' international credibility.



Existing sales and distribution platform allows immediate access to buyers of Generic and branded prescription drug in the US market



Zoraya is Senores' strategic U.S. anchor, designed to accelerate drug development, regulatory compliance, and market expansion in the US.



The strategic initiative will strengthen our forward integration.

Presence in the Emerging & Mid-Tier Markets with Portfolio including Specialty and Niche Products

Special Focus

Niche & Specialty patented products in the US with early launch opportunity in Emerging Markets

Sugammadex



Ferric Carboxymaltose



Tofacitinib



Sacubitril + Valsartan



Apixaban



Eltrombopag Olamine



Diverse Business Models

P2P Model

CDMO Model

Distributor Model

Own Brands

40+

Countries Marketed

1,502


Total Products

558

Product Registrations

944

Product Applications Filed



109 | 14
Registered | Filed



196 | 445
Registered | Filed



44 | 172
Registered | Filed



206 | 298
Registered | Filed



3 | 14
Registered | Filed

Entered EU and Other Mid-Tier Markets with 15 Approved Products as of September 2026

Top Emerging Markets

Philippines



Peru



Ghana



Nigeria



Myanmar



Guatemala



Kenya



Branded Generics Business – Key Highlights

60+

Products Launched


100+

Total Employees

200+

Hospitals Served

Key Partners



Professional and Experienced Management Team (1/2)



Swapnil Jatinbhai Shah
Promoter & Managing Director

- Nearly 2 decades of experience in the pharma sector
- Part of the core management team & leads overall company functions: product portfolio, corporate strategy, business development, strategic management



Sanjay Shaileshbhai Majmudar
**Chairman & Non-Executive,
Non- Independent Director**

- 40+ years of experience
- Director on the board of AIA Engineering Ltd., Ashima Ltd., M&B Engineering Ltd. & Welcast Steels Ltd.



Deval Rajnikant Shah
Whole-Time Director & CFO

- 40+ years of experience in Pharma, Engineering & Chartered Accountancy
- Previously associated with SAI Consulting Engineers Pvt. Ltd. as CFO



Chetan Bipinchandra Shah
Whole-Time Director & COO

- 25+ years of experience in Pharma
- Previously associated with Torrent Pharma & Cadila Pharma. Also associated with Reliance Retail Ltd., Reliance Fresh Ltd. & Reliance Corporate IT Park Ltd.



**Jitendra Babulal Sanghvi Non-
Executive, Non-Independent
Director**

- 17+ years of Total experience
- Spearheading Ratnatris Pharmaceuticals as the Director for nearly two decades, since Aug 11, 2009.



Ashokkumar Vijaysinh Barot
**Promoter, Non-Executive,
Non- Independent Director**

- 21+ years of Pharmaceutical experience
- Non-Executive Director on the board of Di-Cal Pharma Pvt. Ltd. Since Nov 6, 2008. Registered pharmacist with the state pharmacy council of Gujarat

Professional and Experienced Management Team (2/2)



Jignesh Desai
President - Finance

- 30+ years of experience in finance and accounting
- Qualified CA by profession
- Previously associated with Cadila Pharmaceuticals, Gokul Refoil & Solvent, Zydus Cadila, and Ashima Denim.



Gautam Shah
President - US Operations

- 30+ years of experience in pharmaceutical industry
- Held leadership roles at leading pharmaceutical companies like Cipla, Sun Pharma, Caraco Pharmaceutical, Dow Corning, Accord Healthcare, etc.



Jatin Gajjar
Chief Technology Officer

- 30+ years of experience in pharmaceutical technology, manufacturing operations, and product development
- Previously associated with Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma and Aventis Pharma



H. S. Shaktawat
Assistant Vice President - Human Resources

- 25+ years of experience in strategic HR leadership, talent management, and organizational development.
- Previously associated with Sanghi Industries, Cadila Pharmaceuticals, Torrent Pharmaceuticals, Ratnamani Metals & Tubes.



Deepak Jain
Vice President Regulatory Affairs

- Nearly 2 decades of Pharmaceutical experience
- Previously Associated with Cadila Healthcare Ltd. as Deputy General Manager



Sanjay Moralwar
Head - IT


- 36+ years of experience
- Previously associated with CMS Computers Pvt. Ltd, Bajaj Auto Limited, Torrent Pharmaceuticals and Zydus Lifesciences.



Mehul Patel
Vice President – Techno Commercial

- Nearly 2 decades in Formulation Development, technology transfer, and launch execution for Complex Oral Solid products.
- Previously associated with Zydus, Cadila, Wockhardt, etc.

Strong R&D Capabilities Driving Differentiated Product Portfolio



R&D Site 1 - USA

In-House R&D in US for Controlled Substances



Research

Internal research
Information available
on subscribed
databases



R&D Site 2 - India

Consolidating R&D activities
at Ahmedabad. R&D Centre
spread around 11,750 sq. ft



Team

107 people & 3 members
having doctoral qualifications



R&D Site 3 - India

Multi-dosage form R&D capabilities
and a state-of-the-art Quality
Control laboratory for testing and
release of all finished products



Margin

The focus on R&D has allowed
the company to maintain high
profit margins compared to its
industry peers



Accredited FDF Manufacturing Facilities (1/2)

Atlanta Facility

Facility

3

Manufacturing Lines

185,300 Sq. Ft.

Total Area



Strong Regulatory Track Record



USFDA
Approved

5 USFDA | Received no Form
483 & 8 Customer Audits



DEA
Compliant

Eligible for Manufacturing
Controlled Substances



BAA
Compliant

Ability to caters to
Government Supplies

OSD

1.5 Bn units

Annual Installed
Capacity

Ahmedabad, Chhatral Facility



378,943 Sq. Ft.

Total Area

12

Manufacturing Lines

4

Dosage Forms

General Oral Dosage

1,397.96 Mn

Annual Installed
Capacity

Injectables

49.92 Mn

Annual Installed
Capacity

Beta Lactum Orals

511.68 Mn

Annual Installed
Capacity

Facility Approvals



Accredited FDF Manufacturing Facilities (2/2)

Apnar Pharma Plant

- ✓ Manufacturing facility commenced in 2021 & **USFDA Approval received in September 2022 & in September 2026.**
- ✓ 2 land parcel available of total land area of **~49,250 Sq. Mts.**
- ✓ Facility constructed on 1 plot (~4,500 Sq. Mts) with construction of ~40,000 Sq. Ft. Larger plot with ample land **available for future expansion**
- ✓ Employees Strength: **150+ Employees**
- ✓ The facility integrates manufacturing with strong multi-dosage form **R&D capabilities** and an advanced **Quality Control Lab** dedicated to testing and releasing all finished products.
- ✓ Facility is compliant with **clean rooms** for expansion into **other dosage forms**



Tablets

275 Mn

Annual Installed
Capacity

Expandable up to
600 Mn

Capsules

225 Mn

Annual Installed
Capacity

Expandable up to
500 Mn

Bottles

16 Mn

Annual Installed
Capacity

Expandable up to
32 Mn



Strong Regulatory Approvals

USFDA

MHRA

**Health
Canada**

Accredited API Manufacturing Facilities

Senores API Plant I & II

- ✓ **GMP and WHO-GMP Approved sites**
- ✓ Land parcel of **15,134 sq. ft.** and **230,000 sq. ft.** respectively.
- ✓ Employee Strength: **110+ Employees**
- ✓ The facility integrates manufacturing with an advanced **Quality Control Lab** dedicated to testing and releasing all products.
- ✓ **17+** Products already **commercialized**.
- ✓ **5+** Products in **development**.
- ✓ **3 DMFs** under finalization to be filed for triggering the **USFDA audit**.

Unit I

25 MT
Annual Installed
Capacity

Unit II

144 MT
Annual Installed
Capacity



The API plant II is approvable by USFDA

Great Place to Work with Active Member of Globally recognized Pharma Associations

Great Place To Work Certified



Great Place To Work®
Certified
MAY 2026–MAY 2027
INDIA



We're Great Place To Work® Certified™

Active Member of Various **Globally Recognized Pharmaceutical Associations & Working Bodies**



Confederation of Indian Industry



THE INDIAN PHARMACEUTICAL ASSOCIATION (IPA)
...CRUSADE FOR THE PROFESSION



SENORES PHARMACEUTICALS LIMITED

CONTACT US



Senores Pharmaceuticals Limited

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

investors@senorespharma.com



Strategic Growth Advisors Private Limited

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Tanay Shah
sagar.shroff@sgapl.net / tanay.shah@sgapl.net
+91 98205 19303 / +91 98333 91899